- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02805296
High Intensity Phototherapy: Double vs. Single
Intensive Phototherapy, Double vs. Single, in Treatment of Neonatal Hyperbilirubinemia Using LED
Study Overview
Detailed Description
Hyperbilirubinemia occurs in 60 - 80 % of newborns during the first days of life, among others because of immaturity of the enzyme uridin-glukuronosyl-transferase (UGT1A1) in the liver. In seldom cases with very high total serum bilirubin concentration (TsB), bilirubin can cross the blood-brain barrier and the deposition of unconjugated bilirubin in the central nervous system may cause acute bilirubin encephalopathy (ABE). This can progress to chronic bilirubin encephalopathy (CBE), a devastating condition, which unfortunately still occurs, even in industrialised countries.
Hyperbilirubinemia gets severe for 2 - 6 % of infants born at term or late preterm, which means, they need treatment to prevent ABE and the treatment of choice is phototherapy due to its efficacy and safety. Hereby bilirubin in the skin and plasma is converted to photobilirubins; they are water-soluble and can be excreted through the liver without conjugation. They are presumably non-toxic. In most departments, single phototherapy is first choice. To avoid the above-mentioned damaging condition, it is very important to optimize phototherapy.
Former fluorescent tubes were used as light source, but now light emission diodes (LED) are used.
This study investigates whether double phototherapy reduces total serum bilirubin faster than single light during intensive phototherapy, using LED, and whether there is an upper limit for the efficacy of phototherapy.
It is a prospective, randomised controlled study. The infants will be randomized to either 1: Conventional phototherapy with blue LED light from above and a distance from light source to mattress of 30 cm, giving a light irradiance of 66 µW/cm2/nm or 2: Conventional phototherapy combined with a light blanket (Bilisoft) with a light irradiance by the skin of 39 µW/cm2/nm. TsB will be measured at start and after 12 - and 24 h of treatment. Based on the calculation of strength 72 infants will be needed in this study. As statistical methods t-tests will be used and multiple linear regression models will be used to adjust for confounding.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Otherwise healthy newborn infants with hyperbilirubinemia without signs of hemolytic disease
- gestational age ≥33 weeks
- birth weight ≥1800 g
- The infants should be treatable in a cradle
Exclusion Criteria:
- Infants fulfilling the indications for exchange transfusion or double phototherapy due to a very high initial or rapidly increasing TsB will not be enrolled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Double light
High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below. Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm |
Comparison of double vs. single phototherapy
|
Active Comparator: Single light
High-intensity phototherapy with blue LED light from above.
Intervention: Light irradiance: 66 µW/cm2/nm
|
Comparison of double vs. single phototherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in total serum bilirubin after 12- and 24 hours of phototherapy, measured in percent.
Time Frame: 12 and 24 Hours og phototherapy
|
Total serum bilirubin will be measured at start of phototherapy, after 12 - and after 24 hours of phototherapy for both Groups.
Primary outcome measure is, whether double phototherapy decreases total serum bilirubin faster than single phototherapy after 12- and/or after 24 hours of phototherapy.
|
12 and 24 Hours og phototherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Whether total serum bilirubin continues to decrease measured in percent after 24 hours of high-intensity phototherapy
Time Frame: 24 Hours of phototherapy
|
To figure out, whether there is an upper limit for the efficacy of phototherapy, i.e. a plateau above which total serum bilirubin does not decrease any further.
|
24 Hours of phototherapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mette L Roed, MD, Aalborg University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-20140010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperbilirubinemia
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingNeonatal HyperbilirubinemiaChina
-
Region Örebro CountyCompleted
-
University of PatrasCompleted
-
Hacettepe UniversityCompletedHyperbilirubinemia, Neonatal IndirectTurkey
-
University of AarhusCompletedUncomplicated Neonatal HyperbilirubinemiaDenmark
-
Princess Amalia Children's ClinicNot yet recruiting
-
University of OxfordKinshasa School of Public HealthCompletedNeonatal HyperbilirubinemiaCongo, The Democratic Republic of the
-
University of AarhusUnknownNeonatal Hyperbilirubinemia
-
University of OxfordCompletedNeonatal Hyperbilirubinemia
-
Karadeniz Technical UniversityCompletedNeonatal Hyperbilirubinemia
Clinical Trials on Light irradiance
-
Nagoya UniversityTerminated
-
University of AarhusUnknownNeonatal Hyperbilirubinemia
-
Stephen TrokelWithdrawn
-
Icahn School of Medicine at Mount SinaiRecruitingMild Cognitive ImpairmentUnited States
-
China Medical University HospitalNot yet recruiting
-
University Hospital, Strasbourg, FranceRecruiting
-
Shanghai Zhongshan HospitalFudan University; Shanghai Mental Health Center, Jingan District; Shanghai Mental...Unknown
-
L'OrealCompletedSkin Aging | Radiation Tolerance | RhytidsUnited States
-
Matthew Neal MDTerminatedPancreatic Neoplasms | Rectal NeoplasmsUnited States
-
Rogers Sciences Inc.Unknown